Abstract: A modified nucleoside or nucleotide, the 3?-OH of the modified nucleoside or nucleotide being reversibly blocked; meanwhile, the present invention also relates to a kit comprising the nucleoside or nucleotide, and a sequencing method based on the nucleoside or nucleotide.

Abstract: Provided are a method for sequencing polynucleotides based on optical signal kinetics of luminescent labels and secondary luminescent signals, in which different luminescence forms and luminescence timings are applied to distinguish the sequential incorporation of different nucleotides, so as to realize the sequencing of the polynucleotides.

Abstract: Provided are a method for detecting spatial information of nucleic acids in a sample, as well as a nucleic acid array used in the method and a method for producing the nucleic acid array.

Abstract: The present invention provides a sequencing method based on a single fluorescent dye, in which a self-luminescence signal is used to distinguish the sequential incorporation of different nucleotides, thereby realizing the determination of the polynucleotide sequence.

Abstract: Provided are a rolling circle amplification method, a method for preparing a sequencing library, and a DNA nanoball prepared therefrom. The rolling circle amplification method includes: sequentially denaturing and annealing a double-stranded DNA and a mediating sequence in a same system, to complementarily pair the mediating sequence with two ends of a denatured single-stranded DNA; simultaneously introducing a ligase and a polymerase into the system to connect the two ends of the single-stranded DNA under action of the ligase; and performing a rolling circle amplification reaction under action of the polymerase by using the mediating sequence as a primer and the single-stranded DNA as a template, to obtain DNA nanoball.

Abstract: The present invention provides a method for sequencing polynucleotides. Sequential incorporation of different nucleotides is detected by using the same light emitting signal, thereby achieving the determination of polynucleotide sequences.

Abstract: Provided is a method for sequencing a long-fragment nucleic acid. The nucleic acid molecules each containing a long insert, a first sequencing adapter, and a second sequencing adapter, is used to construct a sequencing library, and the sequencing is performed in segments to sequence the nucleic acids having the long inserts.

Abstract: Use of isopropyl ?-(3,4-dihydroxyphenyl)-?-hydroxypropionate (IDHP) in the preparation of a drug or a health product for prevention and treatment of coronary atherosclerosis diseases. The IDHP can also be used to inhibit platelet aggregation, to promote angiogenesis, and to prepare a drug and a health product for prevention and treatment of senile vascular dementia.

Abstract: Use of isopropyl ?-(3,4-dihydroxyphenyl)-?-hydroxypropionate (IDHP) in the preparation of a drug or a health product for prevention and treatment of coronary atherosclerosis diseases. The IDHP can also be used to inhibit platelet aggregation, to promote angiogenesis, and to prepare a drug and a health product for prevention and treatment of senile vascular dementia.

Abstract: Recombinant Fc fusion proteins of human follicle-stimulating hormone (hFSH) with in vivo biological activities comparable to those of human follicle-stimulating hormone are disclosed. A recombinant hFSH-Fc fusion protein comprises ? subunit of hFSH (hFSH ?), CTP, ? subunit of hFSH (hFSH ?), a flexible peptide linker, and human IgG2 Fc variant (vIgG2Fc). A method is also disclosed to make such fusion proteins at good expression levels. These recombinant hFSH-Fc fusion proteins of the present disclosure exhibit sufficient biological activities and prolonged plasma half-lives, leading to improved pharmacokinetics and pharmacodynamics. Thus, a lower dosage may be used and/or better or different therapeutic efficacies with less side effects may be achieved. A method for the application of the recombinant hFSH-Fc fusion proteins in the treatment and/or prevention of human infertility is also disclosed.

Abstract: The present disclosure provides methods and pharmaceutical compositions for treating depigmentation diseases such as vitiligo or leukoctricia. The pharmaceutical composition contains a therapeutically effective amount of fluoxetine.

Abstract: Recombinant Fc fusion proteins of human follicle-stimulating hormone (hFSH) with in vivo biological activities comparable to those of human follicle-stimulating hormone are disclosed. A recombinant hFSH-Fc fusion protein comprises ? subunit of hFSH (hFSH ?), CTP, ? subunit of hFSH (hFSH ?), a flexible peptide linker, and human IgG2 Fe variant (vIgG2Fc). A method is also disclosed to make such fusion proteins at good expression levels. These recombinant hFSH-Fc fusion proteins of the present disclosure exhibit sufficient biological activities and prolonged plasma half-lives, leading to improved pharmacokinetics and pharmacodynamics. Thus, a lower dosage may be used and/or better or different therapeutic efficacies with less side effects may be achieved. A method for the application of the recombinant hFSH-Fc fusion proteins in the treatment and/or prevention of human infertility is also disclosed.

Abstract: The present disclosure provides methods and pharmaceutical compositions for treating depigmentation diseases such as vitiligo or leukoctricia. The pharmaceutical composition contains a therapeutically effective amount of fluoxetine.

Abstract: The present invention relates to the field of medicine and particularly relates to the application of fluoxetine to the treatment of depigmentation diseases. Pharmacodynamic tests have demonstrated that fluoxetine has the effects of treating depigmentation diseases especially leukotrichia and vitiligo.